Glenmark Pharmaceuticals gets final ANDA approval for Fluocinonide Cream

From US Food and Drug Administration

Glenmark Pharmaceuticals announced that Glenmark Generics Inc., USA, the subsidiary of Glenmark Generics, has been granted final approval from the United States Food and Drug Administration (US FDA) for its abbreviated new drug application (ANDA) for Fluocinonide Cream USP 0.1%, the generic version of Vanos Cream by Medicis.

Fluocinonide Cream is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses. According to IMS Health sales data for the 12 month period ending March 2014, Fluocinonide Cream garnered annual sales of approximately USD 103 million.

Powered by Capital Market - Live News